Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
PR Newswire —
The secondary analysis of the PACE trial highlights the value of counting Circulating Tumor Cells (CTCs) in the blood to help guide treatment escalation or de-escalation in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer whose disease...